RICE HALL JAMES & ASSOCIATES, LLC - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 208 filers reported holding NEKTAR THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.

Quarter-by-quarter ownership
RICE HALL JAMES & ASSOCIATES, LLC ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q2 2021$8,487,000
-25.0%
494,568
-12.6%
0.30%
-18.2%
Q1 2021$11,322,000
+17.2%
566,082
-0.4%
0.37%
+8.5%
Q4 2020$9,662,000
-1.8%
568,379
-4.1%
0.34%
-14.1%
Q3 2020$9,837,000
-24.9%
592,930
+4.8%
0.40%
-29.7%
Q2 2020$13,105,000
+25.8%
565,833
-3.0%
0.56%
-3.3%
Q1 2020$10,416,000
-19.2%
583,525
-2.2%
0.58%
+33.5%
Q4 2019$12,885,000
+14.5%
596,928
-3.4%
0.44%
+8.5%
Q3 2019$11,251,000
-49.8%
617,674
-2.0%
0.40%
-46.0%
Q2 2019$22,415,000
-0.5%
629,999
-6.0%
0.74%
+2.8%
Q1 2019$22,524,000
+5.6%
670,359
+3.3%
0.72%
-6.8%
Q4 2018$21,333,000
-22.9%
649,002
+42.9%
0.78%
-21.5%
Q3 2018$27,678,000
+21.9%
454,032
-2.3%
0.99%
+20.1%
Q2 2018$22,700,000
-53.7%
464,883
+0.8%
0.82%
-56.9%
Q1 2018$48,985,000
-20.3%
460,993
-55.2%
1.91%
-20.9%
Q4 2017$61,472,000
+107.0%
1,029,332
-16.8%
2.42%
+83.9%
Q3 2017$29,695,000
+17.8%
1,237,309
-4.1%
1.31%
+19.9%
Q2 2017$25,214,000
+4.8%
1,289,717
+25.8%
1.10%
-6.5%
Q1 2017$24,060,000
+90.6%
1,025,147
-0.4%
1.17%
+84.0%
Q4 2016$12,624,000
-29.9%
1,028,819
-1.8%
0.64%
-32.3%
Q3 2016$18,000,000
+35.6%
1,047,750
+12.3%
0.94%
+23.0%
Q2 2016$13,276,000
+4.9%
932,933
+1.4%
0.76%
+4.8%
Q1 2016$12,652,000
-16.5%
920,121
+2.3%
0.73%
-15.7%
Q4 2015$15,157,000
+164.9%
899,531
+72.3%
0.87%
+134.1%
Q3 2015$5,721,000
-4.8%
521,967
+8.7%
0.37%
+6.6%
Q2 2015$6,007,000
+3.5%
480,161
-9.0%
0.35%
+3.3%
Q1 2015$5,803,000
-18.6%
527,575
+14.7%
0.34%
-22.4%
Q4 2014$7,131,000
+53.4%
460,093
+19.4%
0.43%
+33.6%
Q3 2014$4,650,000
+100.0%
385,244
+112.4%
0.32%
+107.7%
Q2 2014$2,325,000
+54.7%
181,338
+46.3%
0.16%
+41.8%
Q1 2014$1,503,000
+92.4%
123,990
+80.3%
0.11%
+96.4%
Q4 2013$781,000
+192.5%
68,787
+169.4%
0.06%
+115.4%
Q3 2013$267,000
-25.2%
25,538
-17.4%
0.03%
-25.7%
Q2 2013$357,00030,9270.04%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q3 2017
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders